Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 203b (MIR203B) is a short non-coding RNA molecule in the microRNA family, primarily functioning as a post-transcriptional regulator of gene expression[3]. It acts as a tumor suppressor in several types of cancer, including hepatocellular carcinoma and basal cell carcinoma, by inhibiting mRNAs such as MAT2A, MAT2B, RUNX2, LIN28B, and c-JUN, leading to reduced proliferation, increased apoptosis, and promotion of differentiation in affected cells[1][2]. Its expression is often downregulated in cancers where it normally exerts these suppressive effects[1][2]. MIR203B may serve as a candidate biomarker for prognosis and patient selection in cancer therapy[1].
Post-transcriptional gene silencing, mRNA degradation or translational repression of specific oncogenes and cell proliferation genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 203b (MIR203B).